112 related articles for article (PubMed ID: 2519837)
21. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
22. B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity.
Selmayr M; Menzel H; Kremer JP; Thierfelder S; Mocikat R
Cancer Gene Ther; 2000 Mar; 7(3):501-6. PubMed ID: 10766357
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of a murine B cell tumor with antibodies and F(ab')2 fragments against idiotypic determinants of its cell surface IgM.
Perek Y; Hurwitz E; Burowski D; Haimovich J
J Immunol; 1983 Sep; 131(3):1600-3. PubMed ID: 6604103
[TBL] [Abstract][Full Text] [Related]
24. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection.
Benvenuti F; Burrone OR; Efremov DG
Gene Ther; 2000 Apr; 7(7):605-11. PubMed ID: 10819576
[TBL] [Abstract][Full Text] [Related]
25. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.
Cesco-Gaspere M; Benvenuti F; Burrone OR
Cancer Immunol Immunother; 2005 Apr; 54(4):351-8. PubMed ID: 15692846
[TBL] [Abstract][Full Text] [Related]
26. Human monoclonal antibodies produced in transgenic BABkappa,lambda mice recognising idiotypic immunoglobulins of human lymphoma cells.
Suárez E; Yáñez R; Barrios Y; Díaz-Espada F
Mol Immunol; 2004 Jul; 41(5):519-26. PubMed ID: 15183930
[TBL] [Abstract][Full Text] [Related]
27. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
[TBL] [Abstract][Full Text] [Related]
28. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice.
Racila E; Scheuermann RH; Picker LJ; Yefenof E; Tucker T; Chang W; Marches R; Street NE; Vitetta ES; Uhr JW
J Exp Med; 1995 Apr; 181(4):1539-50. PubMed ID: 7535341
[TBL] [Abstract][Full Text] [Related]
29. Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells.
Marches R; Racila E; Tucker TF; Picker L; Mongini P; Hsueh R; Vitetta ES; Scheuermann RH; Uhr JW
Ther Immunol; 1995 Jun; 2(3):125-36. PubMed ID: 8885131
[TBL] [Abstract][Full Text] [Related]
30. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation.
Stevenson FK; Gordon J
J Immunol; 1983 Feb; 130(2):970-3. PubMed ID: 6600259
[TBL] [Abstract][Full Text] [Related]
31. B-1a cell origin of the murine B lymphoma line BCL1 characterized by surface markers and bacterial reactivity of its surface IgM.
Koganei S; Ito M; Yamamoto K; Matsumoto N
Immunol Lett; 2005 May; 98(2):232-44. PubMed ID: 15860223
[TBL] [Abstract][Full Text] [Related]
32. Idiotypic intramolecular help. Induction of tumor-specific antibodies by monoclonal anti-idiotypic antibody with the help of Fc-specific T helper clones.
Saeki Y; Chen JJ; Shi LF; Kohler H
J Immunol; 1989 Apr; 142(8):2629-34. PubMed ID: 2522964
[TBL] [Abstract][Full Text] [Related]
33. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype.
Selmayr M; Strehl J; Kremer JP; Kremmer E; Doenecke A; Hallek M; Menzel H; Thielemans K; Thierfelder S; Mocikat R
Gene Ther; 1999 May; 6(5):778-84. PubMed ID: 10505101
[TBL] [Abstract][Full Text] [Related]
34. Cancer dormancy: studies of the murine BCL1 lymphoma.
Uhr JW; Tucker T; May RD; Siu H; Vitetta ES
Cancer Res; 1991 Sep; 51(18 Suppl):5045s-5053s. PubMed ID: 1884380
[TBL] [Abstract][Full Text] [Related]
35. Idiotypes on B lymphocytes: association with immunoglobulins.
Victor C; Bona C; Pernis B
J Immunol; 1983 Apr; 130(4):1819-25. PubMed ID: 6187821
[TBL] [Abstract][Full Text] [Related]
36. Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas.
Thielemans K; Maloney DG; Meeker T; Fujimoto J; Doss C; Warnke RA; Bindl J; Gralow J; Miller RA; Levy R
J Immunol; 1984 Jul; 133(1):495-501. PubMed ID: 6609992
[TBL] [Abstract][Full Text] [Related]
37. Expression of two cross-reactive idiotypes on mouse antibodies against bromelain-treated mouse erythrocytes.
Kawaguchi S
Immunology; 1987 Aug; 61(4):391-6. PubMed ID: 3327804
[TBL] [Abstract][Full Text] [Related]
38. [The analysis of immunoregulation of idiotype synthesis by monoclonal anti-idiotypic antibody].
Fujisaku A
Hokkaido Igaku Zasshi; 1986 Jan; 61(1):134-45. PubMed ID: 3084367
[TBL] [Abstract][Full Text] [Related]
39. Idiotype identity in a MALT-type lymphoma and B cells in Helicobacter pylori associated chronic gastritis.
Greiner A; Marx A; Heesemann J; Leebmann J; Schmausser B; Müller-Hermelink HK
Lab Invest; 1994 Apr; 70(4):572-8. PubMed ID: 8176897
[TBL] [Abstract][Full Text] [Related]
40. In vivo tumor immunotherapy by a bacterial superantigen.
Ochi A; Migita K; Xu J; Siminovitch K
J Immunol; 1993 Sep; 151(6):3180-6. PubMed ID: 8376773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
